EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway

Songtao Gu, Jingjing Liang, Jianwei Zhang, Zhichao Liu, Yang Miao, Yuli Wei, Shimeng Li, Jinying Gu, Yunyao Cui, Ting Xiao, Xiaohe Li, Cheng Yang

Molecules · 27.02.2023 · 28 (5) · 2195

DOI: 10.3390/molecules28052195 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, online erschienen am 27.02.2023. Verfasst von Songtao Gu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory & Critical Care Medicine, Tianjin Chest Hospital, No. 261 Taierzhuang South Road, Jinnan District, Tianjin 300222, China. Hauptthemen laut MEDLINE: Transforming Growth Factor beta1, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for the Central Universities, Foundation of Organ Fibrosis Druggability Joint Research Centre of Nankai and Guokaixingcheng.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive interstitial lung disease with unknown etiology, high mortality and limited treatment options. It is characterized by myofibroblast proliferation and extensive deposition of extracellular matrix (ECM), which will lead to fibrous proliferation and the destruction of lung structure. Transforming growth factor-β1 (TGF-β1) is widely recognized as a central pathway of pulmonary fibrosis, and the suppression of TGF-β1 or the TGF-β1-regulated signaling pathway may thus offer potential antifibrotic therapies. JAK-STAT is a downstream signaling pathway regulated by TGF-β1. JAK1/2 inhibitor baricitinib is a marketed drug for the treatment of rheumatoid arthritis, but its role in pulmonary fibrosis has not been reported. This study explored the potential effect and mechanism of baricitinib on pulmonary fibrosis in vivo and in vitro. The in vivo studies have shown that baricitinib can effectively attenuate bleomycin (BLM)-induced pulmonary fibrosis, and in vitro studies showed that baricitinib attenuates TGF-β1-induced fibroblast activation and epithelial cell injury by inhibiting TGF-β1/non-Smad and TGF-β1/JAK/STAT signaling pathways, respectively. In conclusion, baricitinib, a JAK1/2 inhibitor, impedes myofibroblast activation and epithelial injury via targeting the TGF-β1 signaling pathway and reduces BLM-induced pulmonary fibrosis in mice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transforming Growth Factor beta1Idiopathic Pulmonary FibrosisMiceAnimalsBleomycinLungSignal TransductionFibroblastsMice, Inbred C57BLAzetidinesPurinesPyrazolesSulfonamides

Stichwörter der Autor:innen

JAK-STATTGF-β1 signaling pathwaybaricitinibpulmonary fibrosis

Substanzen

Transforming Growth Factor beta1BleomycinbaricitinibAzetidinesPurinesPyrazolesSulfonamides

Autor:innen und Institutionen

  • Department of Respiratory & Critical Care Medicine, Tianjin Chest Hospital, No. 261 Taierzhuang South Road, Jinnan District, Tianjin 300222, China.
  • State Key Laboratory of Medicinal Chemical Biology, College of Pharmacy and Tianjin Key Laboratory of Molecular Drug Research, Nankai University, Haihe Education Park, 38 Tongyan Road, Tianjin 300353, China.
  • Tianjin Key Laboratory of Molecular Drug Research, Tianjin International Joint Academy of Biomedicine, Tianjin 300457, China.
  • Tianjin Jikun Technology Co., Ltd., Tianjin 301700, China.

Förderung

  • National Natural Science Foundation of China
  • Fundamental Research Funds for the Central Universities
  • Foundation of Organ Fibrosis Druggability Joint Research Centre of Nankai and Guokaixingcheng
  • Fundamental Research Funds for the Central Universities, Nankai University

Zitieren

APA

Gu, S., Liang, J., Zhang, J., Liu, Z., Miao, Y., Wei, Y., Li, S., Gu, J., Cui, Y., Xiao, T., Li, X., & Yang, C. (2023). Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway. Molecules, 28(5), 2195. https://doi.org/10.3390/molecules28052195

Vancouver

Gu S, Liang J, Zhang J, Liu Z, Miao Y, Wei Y, et al. Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway. Molecules. 2023;28(5):2195. doi:10.3390/molecules28052195

BibTeX
@article{Gu2023,
  author = {Gu, Songtao and Liang, Jingjing and Zhang, Jianwei and Liu, Zhichao and Miao, Yang and Wei, Yuli and Li, Shimeng and Gu, Jinying and Cui, Yunyao and Xiao, Ting and Li, Xiaohe and Yang, Cheng},
  title = {Baricitinib Attenuates Bleomycin-Induced Pulmonary Fibrosis in Mice by Inhibiting TGF-β1 Signaling Pathway},
  journal = {Molecules},
  year = {2023},
  volume = {28},
  number = {5},
  pages = {2195},
  doi = {10.3390/molecules28052195}
}
Kostenlos starten →